Join Dana Rizk, MD (University of Alabama at Birmingham, USA), and Shikha Wadhwani, MD (Indiana University School of Medicine, USA), for a conversation on the treatment revolution in IgAN. They discuss how breakthroughs in understanding disease pathophysiology are fueling a wave of new therapies that go beyond traditional supportive care.

Key topics include what's changed since the KDIGO 2021 Guideline, the four-hit hypothesis and its role in driving novel therapies, key factors to consider when selecting treatments, and the evolving role of traditional approaches alongside newer agents.

This podcast was supported by Travere.